Roche Says Giredrestrant Combination Improved Progression-Free Survival In Phase III Study

By Reuters News

Oct 1 (Reuters) - ROCHE HOLDING AG ROPC.S:

  • ROCHE’S GIREDESTRANT COMBINATION SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN ER-POSITIVE ADVANCED BREAST CANCER IN PHASE III EVERA DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

  • FDA SETS PDUFA GOAL DATE FOR GIREDRESTRANT ON NOV 30 AND DEC 18, 2026

  • GIREDRESTRANT COMBINATION SHOWS MANAGEABLE ADVERSE EVENTS WITH NO UNEXPECTED SAFETY FINDINGS

  • GIREDRESTRANT PLUS EVEROLIMUS REDUCES RISK OF DISEASE PROGRESSION OR DEATH BY 44%-62%

  • MEDIAN PFS 8.8 MONTHS WITH GIREDRESTRANT PLUS EVEROLIMUS IN ITT POPULATION

  • OS DATA SHOW POSITIVE TREND IN ITT AND ESR1-MUTATED POPULATIONS

Further company coverage: ROPC.S

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.